Vous n'êtes pas encore inscrit ?Inscription
“GamaMabs Pharma is a clinical-stage immuno-oncology company developing optimized therapeutic antibodies for the treatment of cancer.
GamaMabs’ lead project is the monoclonal antibody (mAb) GM102 which targets Anti-Müllerian Human Receptor II (AMHRII), an unaddressed specific target in cancer.
The company develops low-fucose EMABling® antibodies with increased tumor cell killing properties through the activation of immune system cells. GamaMabs has a licensing agreement with MedImmune (USA) to develop an Antibody Drug Conjugate targeting cancer.” from gamamabs.com